Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A pediatric oncology group pilot study

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 3, 1998, Pages 229-233

  Lauer, Stephen J ^a,i   Camitta, Bruce M ^b   Leventhal, Brigid G ^c   Mahoney Jr , Donald ^d   Shuster, Jonathan J ^e   Kiefer, Geri ^b   Pullen, Jeanette ^f   Philip Steuber, C ^d   Carroll, Andrew J ^g   Kamen, Barton ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Univ of Mississippi Medical Center ^*  (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ NONE   (United States)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Infant leukemia

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; RISK BENEFIT ANALYSIS; SEPSIS; TREATMENT FAILURE;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCORTISONE; INFANT; INJECTIONS, SPINAL; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; PILOT PROJECTS; REMISSION INDUCTION; TENIPOSIDE;

EID: 0031813927     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199805000-00008     Document Type: Article

References (34)

1. Kardos G, Revesz T, Koos R, et al. Infant leukemia in Hungary. Med Pediatr Oncol 1982;10:201-7.
2. Reaman G, Zeltzer P. Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: accumulative experience of the Children's Cancer study group. J Clin Onc 1985;3:1515-21.
3. Crist W, Pullen J, Boyett J, et al. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemia in infants: a Pediatnc Oncology Group study. Blood 1986;67:135-40.
4. Felix CA, Reaman GH, Korsmeyer SJ, et al. Immunoglobulin and T cell receptor gene configuration in acute lymphoblastic leukemia of infancy. Blood 1987;70:536-41.
5. Heerema NA, Arthur DC, Sather H, et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: A report of the Children Cancer Study Group. Blood 1994;83:2274-84.
6. Stark B, Vogel R, Cohen IJ, et al. Biologic and cytogenetic characteristics of leukemia in infants. Cancer 1989;63:117-25.
7. Finkelstein JZ, Higgins GR, Rissman E. Acute leukemia during the first year of life: presentation, chemotherapy and clinical course. Clin Pediatr 1972;11:236-40.
8. Rivera GK, Pinkel D, Simone JV, et al. Treatment of acute lymphoblastic leukemia 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-95.
9. Pui CH. Childhood leukemias. N Engl J Med 1995;332:1618-30.
10. Reaman GH, Steinherz PG, Gaynon PS, et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 1987;71:1033-7.
11. Rivera GA, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337:61-6.
12. Chessells JM, Eden OB, Bailey CC, et al. Acute lymphoblastic leukemia in infancy: experience in MRC UKALL trials report from the Medical Research Council working party on childhood leukemia. Leukemia 1994;8:1275-9.
13. Ferster A, Bertrand Y, Benoit Y, et al. Improved survival for acute lymphoblastic leukemia in infancy: the experience of EORTC - Childhood Leukemia Cooperative Group. Br J Haematol 1994;86:284-90.
14. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia. Results of the Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 1994;12:740-7.
15. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:122-33
16. Frankel LS, Ochs J, Shuster JJ, et al. A therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group Experience (POG #8493). J Pediatr Hematol Oncol 1997;19:35-42.
17. Goldie JH, Coldman AJ, Gudauskas GA, Rationale for the alternating no cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-49.
18. Weinstein HJ, Mayer RJ, Rosenthal DS, et al. Treatment of acute myeogenous leukemia in children and adults. N Engl J Med 1980;303:473-8.
19. Rivera G, Dahl GV, Bowman WP, et al. VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia. Cancer 1980;46:1727-30.
20. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia: identification of a relationship between concentration and effect. N Engl J Med 1988;314;471-7.
21. Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia: a Pediatric Oncology Group pilot study. Cancer 1993;71:2854-61.
22. Pullen DJ, Crist WM, Falletta JM, et al. A Pediatric Oncology Group classification protocol for acute lymphoblastic leukemia (ALinC 13): immunologic phenotypes and correlation with treatment results. In: Murphy SB, Gilbert JR (eds). Leukemia Research: Advances in Cell Biology and Treatment, Vol. 26. Amsterdam: Elsevier, 1983:221-39.
23. Jones B, Breslow N, Takashima J. Toxic deaths in the second National Wilms' Tumor Study. J Clin Oncol 1984;2:1028-33.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Peto R, Pike MC, Armitage P, Breslow NE, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
26. Raimondi SC, Peiper SC, Kitchingman GR, et al. Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood 1989;73:1627-34.
27. Behm FG, Raimondi SC, Frestedt JL, et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia regardless of presenting age. Blood 1996;87:2870-7.
28. Fojo AT, Ueda K, Slamon DJ, et al. I. Expression of a multi-drug resistant gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-9.
29. Bhalla K, Hindenburg A, Taub RN, et al. Isolation and characterization of an anthracycline-resistant human leukemia cell line. Cancer Res 1985;45:3657-62.
30. Pieters R, Huismans DR, Loonen AH, et al. Relations of cellular drug resistance to long term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991;338:399-402.
31. Marks DI, Kurz BW, Link MP, et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997;15:1158-62.
32. Evans WE, Hutson PR, Stewart CF, et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 1983;33:301-7.
33. Kohn W. DNA topoisomerase as targets of anticancer drug action. Proc Am Assoc Cancer Res 1989;30:669-71.
34. Reaman G, Lange B, Feusner J, et al. Intensive systemic and intrathecal chemotherapy improves the outcome for infants with acute lymphoblastic leukemia (ALL) [Abstract]. Proc Am Assoc Clin Oncol 1989;8:211.